INSUFLON CATHETER VS SUBCUTANEOUS INJECTIONS FOR EPOETIN ADMIN IN THE NEONATE

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。背景：促红细胞生成素是一种在肾脏产生的激素，刺激骨髓产生红细胞。10多年来，重组形式的促红细胞生成素，促红细胞生成素α（EPO），已被用于新生儿治疗早产儿贫血。然而，由于这种治疗通常需要每天皮下注射，因此可能会发生疼痛和局部皮肤反应。为了减少这些日常注射引起的不适，有时会在新生儿中使用留置皮下导管（Insulin）。Insulin导管可以插入皮下组织并保持7天。到目前为止，还没有人发表关于Insulin导管在早产儿中输送EPO的临床效用的数据。 目的：在早产儿贫血新生儿中比较Insulin导管与EPO重复皮下注射的安全性、有效性和护士满意度。方法：这是一项前瞻性随机研究。我们将使用向护理需要每日皮下EPO治疗的新生儿的床边护士提供的问卷来测量Insulin导管与标准注射的护士满意度和安全性。为了测量疗效，我们将记录EPO治疗前后这些婴儿的红细胞压积和网织红细胞计数。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Background: Erythropoietin, a hormone produced in the kidney, stimulates bone marrow to produce red blood cells. For over 10 years a recombinant form of erythropoietin, epoetin alfa (EPO), has been used in neonates to treat anemia of prematurity. However, because this treatment often requires daily subcutaneous injections, pain and local skin reactions may occur. In an effort to reduce discomfort caused by these daily injections, an indwelling subcutaneous catheter (Insuflon¿) is sometimes used in the neonate. The Insuflon¿ catheter can be inserted into subcutaneous tissue and remain in place for 7 days. To date, no one has published data concerning the clinical utility of the Insuflon¿ catheter for the delivery of EPO in the premature infant. Purpose: To compare safety, efficacy, and nurse satisfaction of the Insuflon¿ catheter with repeated subcutaneous injections of EPO in neonates with anemia of prematurity. Methods: This is a prospective, randomized study. We will measure nurse satisfaction and safety of the Insuflon¿ catheter versus standard injections using a questionnaire provided to the bedside nurse who cares for neonates requiring daily subcutaneous EPO therapy. To measure efficacy, we will document hematocrit and reticulocyte counts for these infants before and after EPO therapy.